Wednesday, July 8, 2026

Patent intelligence · US

US 8622920

Breath test device and method

granted A61KA61K51/04A61K51/0402A61K51/1206
Status granted
Linked drugs 1
Pipeline programs 5
Years to expiry 7
Applicant portfolio 20
Patent details — US 8622920
Jurisdiction
US
Status
granted
Grant date
Jan 7, 2014
Expiration
Jan 2, 2034
Claims
25
CPC classes
A61K, A61K51/04, A61K51/0402, A61K51/1206
View on Google Patents ↗

Quick answer

US 8622920 (Breath test device and method) is held by EXALENZ BIOSCIENCE LTD.. Status: granted. Granted Jan 7, 2014. Expires Jan 2, 2034 (7 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
25
CPC classes
A61K, A61K51/04, A61K51/0402, A61K51/1206, A61K51/1268

More from EXALENZ BIOSCIENCE LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12414942

    Compositions, methods, and systems for treating presbyopia

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Sep 11, 2045

    granted
  2. US 12180206

    Aceclidine derivatives, compositions thereof and methods of use thereof

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Dec 26, 2044

    granted
  3. US 12128036

    Compositions and methods for storage stable ophthalmic drugs

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Oct 24, 2044

    granted
  4. US 11648247

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires May 11, 2043

    granted
  5. US 11344538

    Methods for the treatment of myopia

    Lenz Therapeutics, Inc. · Expires May 26, 2042

    granted
  6. US 11273150

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires Mar 10, 2042

    granted
  7. US 11214569

    Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof

    Lenz Therapeutics, Inc. · Expires Dec 30, 2041

    granted
  8. US 11179328

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires Nov 18, 2041

    granted

Frequently asked questions

What is US patent 8622920?

US 8622920 (Breath test device and method) is held by EXALENZ BIOSCIENCE LTD.. Status: granted. Granted Jan 7, 2014. Expires Jan 2, 2034 (7 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8622920?

EXALENZ BIOSCIENCE LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.

When does US 8622920 expire?

Our index shows an expiration date of Jan 2, 2034 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.